{"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"FG000","title":"ALK-positive Solid Tumors"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Subject withdrawal of consent"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}